RET and non-small cell lung carcinoma: Among 141 RET fusion-positive NSCLC cases where we had also performed the PD-L1 22C3 CDx assay, 22% (31/141) had a negative TPS score (TPS < 1%), 42% (59/141) had a low positive TPS score (TPS 1–49) and 36% (51/141) had a high positive score (TPS ≥ 50).